Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2013/054145external-prioritypatent/WO2013175388A1/en
Application filed by Novartis AgfiledCriticalNovartis Ag
Publication of CU20140134A7publicationCriticalpatent/CU20140134A7/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invención proporciona un compuesto de la fórmula (A): (A) como se describe en la presente, y sales, enantiomeros, rotámeros, tautómeros, o racemátos de los mismos farmacéuticamente aceptables. También se proporcionan métodos de tratar una enfermedad o condición mediada por la quinasa PIM utilizando compuestos de la Fórmula I, y composiciones farmacéuticas que comprenden tales compuestos.The present invention provides a compound of the formula (A): (A) as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Methods of treating a disease or condition mediated by PIM kinase using compounds of Formula I, and pharmaceutical compositions comprising such compounds are also provided.
DERIVATIVES OF 2- (PIRIDIN-4-IL) PIRIDINE OR SALTS OF THE SAME AS MODULATORS OF PROTEIN QUINASA CDK9 AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM